Screener
BridgeBio Pharma BBIO Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Redeemable convertible noncontrolling interests | (1,018) | (570) |
| Stockholders’ deficit: | ||
| Undesignated preferred stock, $0.001 par value; 25,000,000 shares authorized; no shares issued and outstanding | — | — |
| Common stock, $0.001 par value; 500,000,000 shares authorized; 205,867,350 shares issued and 195,284,352 shares outstanding as of June 30, 2026; 202,369,129 shares issued and 194,771,957 shares outstanding as of December 31, 2025 | 206 | 202 |
| Treasury stock, at cost; 10,582,998 shares as of June 30, 2026; 7,597,172 shares as of December 31, 2025 | (533,279) | (323,276) |
| Additional paid-in capital | 2,155,318 | 2,057,646 |
| Accumulated other comprehensive income (loss) | (7) | 12 |
| Accumulated deficit | (4,137,453) | (3,821,194) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's common stock, par value (in dollars per share)?
- BridgeBio Pharma (BBIO) reported common stock, par value (in dollars per share) of $0 in Q2 2026.
- What does common stock, par value (in dollars per share) mean?
- Common stock, par value (in dollars per share)
Ask your AI about BridgeBio Pharma's common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude